Gmax Biopharm LLC
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2010-09-02
- Employees
- 153
- Market Cap
- -
- Website
- https://www.gmaxbiopharm.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension
Phase 1
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Q4W GMA301 IV injections (1800 mg)Drug: Q4W GMA301 IV injections (300 mg)Drug: Q4W GMA301 IV injections (600 mg)Drug: Q4W GMA301 IV injections (1000 mg)Other: Q4W placebo IV injections
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Gmax Biopharm LLC.
- Target Recruit Count
- 48
- Registration Number
- NCT04503733
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇨🇳Peking Union Medical College Hospital - Dongcheng District, Beijing, China
🇨🇳Xiangya Hospital, Central South University, Changsha, China
News
No news found